Diabetes Obes Metab. 2015 Sep 7. doi: 10.1111/dom.12574. [Epub ahead of print]
IDegLira is a novel combination of a basal insulin (insulin degludec [IDeg]) and a glucagon-like peptide-1 receptor agonist (liraglutide) available as a once-daily injection for patients with type 2 diabetes (T2D). The present post hoc analyses evaluated whether IDegLira was consistently effective regardless of the stage of T2D progression.
MATERIALS AND METHODS:
Using data from the DUAL I extension (insulin-naïve patients uncontrolled on oral antidiabetic drugs [OADs], n=1660, 52-weeks) and DUAL II (patients uncontrolled on basal insulin plus OADs, n=398, 26-weeks) randomized trials, the efficacy of IDegLira was investigated across parameters of disease progression, including baseline HbA1c , disease duration and prior insulin dose.
Across four categories of baseline HbA1c (≤7.5-9.0%), HbA1c reductions were significantly greater with IDegLira (1.1-2.5%) compared with IDeg or liraglutide alone in DUAL I. In DUAL II, HbA1c reductions were significantly greater with IDegLira (0.9-2.5%) versus IDeg in all but the lowest HbA1c category. In DUAL I, insulin dose and hypoglycaemia rate were lower across all baseline HbA1c categories for IDegLira versus IDeg, while hypoglycaemia was higher with IDegLira than liraglutide irrespective of baseline HbA1c . In DUAL II, insulin dose and hypoglycaemia rate were similar with IDegLira and IDeg (max. dose limited to 50 U) independent of baseline HbA1c . Reduction in HbA1c with IDegLira was independent of disease duration and prior insulin dose but varied depending on pre-trial OAD treatment.
IDegLira effectively lowered HbA1c across a range of parameters implying suitability for patients with either early or advanced T2D.
This article is protected by copyright. All rights reserved.